"Its history includes some of the major scientific advances of the nineteenth and twentieth centuries…" On 18th May 1999, Sanofi and Synthélabo officially came together in Paris, France to form ...
« Tarifs douaniers sont les deux plus beaux mots du dictionnaire », a déclaré publiquement Donald Trump en octobre 2024 en ...
Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...
Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to ...
The sale of Sanofi's controlling stake in consumer health business Opella is expected to close in the second quarter at the ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...
Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...
Sanofi SAN1.73%increase; green up pointing triangle forecast stronger earnings growth this year and said it planned to launch a $5.2 billion share buyback. The French pharmaceutical company said ...
Le spécialiste des prestations de location-entretien de linge plat, de vêtements de travail et d'équipements d'hygiène et de bien-être communiquera son chiffre d'affaires du quatrième ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback